Pharmacognostic standardization and anti-obesity evaluation of Boerhavia diffusa involving pancreatic lipase inhibition assays
BIOCHEMICAL AND CELLULAR ARCHIVES · 26.02.2026 · 26 (1) · 497-505
DOI: 10.51470/bca.2026.26.1.497 ↗Kurz gefasst
Fachartikel in der Zeitschrift BIOCHEMICAL AND CELLULAR ARCHIVES, online erschienen am 05.03.2026. Verfasst von C. Narendra und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Obesity is a global metabolic disorder associated with excessive dietary fat absorption, dyslipidaemia, and increased cardiometabolic risk. Pancreatic lipase inhibition represents an effective therapeutic strategy for obesity management; however, existing synthetic inhibitors are associated with adverse gastrointestinal effects. Boerhavia diffusa has been traditionally used in metabolic disorders, yet its anti-obesity potential via pancreatic lipase inhibition remains inadequately validated. The present study aimed to establish pharmacognostic standardisation and evaluate the anti-obesity activity of Boerhavia diffusa. The whole plant was subjected to macroscopic, microscopic, powder microscopic and physicochemical analyses to ensure quality and authenticity. Successive solvent extracts were prepared and screened phytochemically. Quantitative estimation of total phenolic and flavonoid contents was performed. Pancreatic lipase inhibitory activity was evaluated in vitro using a spectrophotometric assay, with orlistat as the reference standard. Stability of the optimised extract was assessed under accelerated conditions. Pharmacognostic evaluation confirmed the diagnostic identity and purity of the plant material. Ethanolic extract exhibited the highest phenolic and flavonoid content and demonstrated significant, concentration-dependent pancreatic lipase inhibition, with an IC50 value of 86.9 ± 6.4 µg/mL. A strong positive correlation was observed between phenolic content and lipase inhibition. Stability studies indicated minimal loss of phytochemical content and bioactivity over three months. In conclusion, the findings validated Boerhavia diffusa as a promising natural pancreatic lipase inhibitor with potential application in obesity management.
Zitieren
APA
Narendra, C., Asharani, M., Mittal, I., Sharma, M., Yadav, D. K., Chakraborty, P., Srivastav, Y., & Ekka, R. S. (2026). Pharmacognostic standardization and anti-obesity evaluation of Boerhavia diffusa involving pancreatic lipase inhibition assays. BIOCHEMICAL AND CELLULAR ARCHIVES, 26(1), 497-505. https://doi.org/10.51470/bca.2026.26.1.497
Vancouver
Narendra C, Asharani M, Mittal I, Sharma M, Yadav DK, Chakraborty P, et al. Pharmacognostic standardization and anti-obesity evaluation of Boerhavia diffusa involving pancreatic lipase inhibition assays. BIOCHEMICAL AND CELLULAR ARCHIVES. 2026;26(1):497-505. doi:10.51470/bca.2026.26.1.497
BibTeX
@article{Narendra2026,
author = {Narendra, C. and Asharani, M. and Mittal, Indu and Sharma, Monika and Yadav, Dhiraj Kumar and Chakraborty, Prapti and Srivastav, Yash and Ekka, Rose Saira},
title = {Pharmacognostic standardization and anti-obesity evaluation of Boerhavia diffusa involving pancreatic lipase inhibition assays},
journal = {BIOCHEMICAL AND CELLULAR ARCHIVES},
year = {2026},
volume = {26},
number = {1},
pages = {497--505},
doi = {10.51470/bca.2026.26.1.497}
}
EUVIMED